Anticoagulation UK

(VTE): Consensus Statement

DEVELOPING OPTIMAL STANDARDS OF CARE FOR THE PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM (VTE): CONSENSUS STATEMEN

During 2018 Anticoagulation UK worked in partnership with the Bristol Myers Squibb Pfizer Alliance to bring together a group of eminent experts to identify actions for improvements in the management of patients at risk of recurrent venous thromboembolism (VTE). The aim of the meeting was for attendees to agree recommendations for the optimal standard of care for patients at risk of recurrent VTE.

The consensus statement is the outcome from this meeting.

Download Statement